Statins including lovastatin have anti-viral, anti-inflammatory, anti-thrombotic, and immunomodulatory features which might play a potential role in treatment and prevention of SARS-CoV-2. Statins alleviate the effects of myocardial damage and thrombosis related to the COVID-19 infection. A case-control study was conducted to evaluate the protective effects of lovastatin in ICU patients with COVID-19.
The study included 284 COVID-19 ICU admitted patients and were divided into 3 groups. The control group consisted of 92 patients who did not receive lovastatin. The second group had 99 patients who received 20 mg/day lovastatin and the third group had 93 patients who received 40 mg/day lovastatin. The results showed that the levels of CRP, IL-6, and IL-8 were significantly reduced in patients receiving lovastatin in a dose-dependent manner than in the control group. Also, the length of hospitalization was significantly reduced in patients receiving lovastatin as compared to the control group. Additionally, the mortality rate in patients receiving lovastatin was lower than the control group.
The mortality rate was 67% in the control group which is very high compared to the 33% mortality rate in patients receiving 40mg lovastatin per day. Thus it can be concluded that lovastatin might have a protective role in COVID -19 patients by reducing the inflammatory response due to SARS-CoV-2 infections and neutrophil recruits to the inflammatory areas. However, further investigations are required for evaluating the effects of lovastatin on the COVID-19 cases, and more clinical trials are needed to confirm the benefits of lovastatin in the treatment of COVID-19 patients.
Ref Link: NCBI
#COVID #Lovastatin #MYOCARDIALDAMAGE #ROLEOFDRUGS
All About COVID-19 For Your Patients
WhiteCoats Insights For Your Practice
Join Thousands of Doctors who Trust WhiteCoats as their Professional Success Partner
For more queries, Call +91-7406-485-000 or mail us at sales@whitecoats.com
Download our App
